Diluted HEPS 1 356.6cps (-3.5% y-y). Normalised Diluted HEPS 688.3cps (-0.4% y-y).
Turnover increased by 9.8% y-y, driven by a strong performance in the Americas (+31.6% y-y) and Europe (+20.3% y-y).
Group GPM down 300bps to 43.5%.
Total expenses up 18.6% y-y, with expenses to sales increasing by 230bps to 31.3%.
OPM decreased by 350bps to 15.7%.
Dividend of 359cps (FY23: 342.0cps).
Commercial Pharmaceutical revenue grew by 3.9% y-y, driven by Prescription and OTC which offset the decline in Injectables revenue.
Net debt increased from R22.2 billion in June 2023 to R26.9 billion in June 2024 with net acquisitions totalling R7.7 billion being key to the rise.
Increased net interest costs, fuelled by higher rates and increased net debt levels, were offset by lower foreign exchange losses resulting from reduced volatility in emerging market currencies relative to the Euro.
The leverage ratio ended at 2.3x comfortably within the Group’s targeted range.
